Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7997923 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3868090 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3980884 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9320884 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL17287304 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3989821 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL17608718 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3856545 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3859291 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9209758 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098841-B2 | Method of inducing a phase transition of a bilayer membrane vesicle | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-1852177-B1 | MOLECULAR AGGREGATE CAPABLE OF UNDERGOING PHASE TRANSITION BY DEHYDRATING CONDENSATION AND METHOD OF PHASE TRANSITION THEREOF | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-02-26 | — | — | EP | disclosed |
| EP-2669002-A1 | Molecular aggregate capable of undergoing phase transition by dehydrating condensation and method of phase transition thereof | Japan Science and Technology Agency (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130251788-A1 | Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8449979-B2 | Molecular aggregate capable of undergoing phase transition by dehydrating condensation and method of phase transition thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20090023003-A1 | Molecular Aggregate Capable of Undergoing Phase Transition by Dehydrating Condensation and Method of Phase Transition Thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1852177-A1 | MOLECULAR AGGREGATE CAPABLE OF UNDERGOING PHASE TRANSITION BY DEHYDRATING CONDENSATION AND METHOD OF PHASE TRANSITION THEREOF | Japan Science and Technology Agency (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098841-B2 | Method of inducing a phase transition of a bilayer membrane vesicle | VAPB, VAPA, NSF | PTPN7 4871/4885HMGCR 795/4885RECQL 1220/4885 |
| US-20130251788-A1 | Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle | VAPB, VAPA, NSF | PTPN7 4871/4885HMGCR 795/4885RECQL 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.